Back to News
Market Impact: 0.3
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
Source: Business Wire
Healthcare & Biotech
CEL-SCI presented Phase 3 Multikine data at the World Congress, reporting that pre-surgical biomarkers identified head and neck cancer patients with 73% five-year survival. The headline provides no comparator, cohort size, or further details on the result.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CVM0.60
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results